Thus, the regulation of RAS-RAF-ERK pathway by targeting the PHB-CRAF interaction introduces a novel potential therapeutic approach for ERK-driven pancreatic cancer. The gene discussed is RAF1; the disease is familial pancreatic carcinoma.